Viemed Healthcare Authorizes Share Repurchase Program Through March 2027

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Mar 04 2026

0mins

Should l Buy VMD?

Viemed Healthcare has authorized a share repurchase program effective through March 2027. Under the share repurchase program, which constitutes a normal course issuer bid under applicable Canadian securities laws, Viemed may purchase up to 1,930,131 common shares of the company from time to time, representing approximately 5% of the total issued and outstanding common shares as of March 4. Daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase. The company may discontinue its purchases at any time, subject to compliance with applicable securities laws. The common shares purchased by the company will be cancelled.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy VMD?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on VMD

About VMD

Viemed Healthcare, Inc. is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. The Company focuses on in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment solutions, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, oxygen concentrators, breast pumps for women, respiratory devices and other medical equipment. It offers in-home sleep apnea testing services. The Company also provides healthcare staffing and recruitment services.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Viemed (VMD) Q4 2025 Earnings Call Transcript

Mar 05 2026NASDAQ.COM

Viemed Healthcare Q4 Earnings Beat Expectations

Mar 05 2026seekingalpha

Earnings Highlights: Viemed Healthcare reported Q4 GAAP EPS of $0.14, beating expectations by $0.05, although revenue of $76.2 million, up 25.5% year-over-year, missed by $1.15 million, indicating challenges in balancing growth and profitability.
Adjusted EBITDA Growth: For the year ending December 31, 2025, adjusted EBITDA reached $18.2 million, with a record $61.4 million for the full year, demonstrating the company's ability to maintain strong profitability amid ongoing growth, which bolsters investor confidence.
Significant Free Cash Flow Increase: The free cash flow for 2025 totaled $28.1 million, a substantial increase from $11.6 million in 2024, reflecting improvements in operational efficiency and cash management, which will support future investments and shareholder returns.
2026 Financial Guidance: The company expects net revenue for 2026 to be in the range of $310 million to $320 million, below the market consensus of $328.73 million, with adjusted EBITDA projected between $65 million and $69 million, indicating a cautiously optimistic outlook for future growth.